
New York-Several promising agents in early stages of development may find a role in the treatment of prostate cancer, and two ongoing cooperative group trials will provide more definitive evidence about how best to use docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer (HRPC). At the Mount Sinai School of Medicine Chemotherapy Foundation Symposium here, the developments were reviewed by Noah M. Hahn, MD, assistant professor of medicine at the Indiana University Cancer Center in Indianapolis.